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To evaluate the cardiovascular risk of polycystic ovary syn-
drome (PCOS), we investigated lipid profile, metabolic pat-
tern, and echocardiography in 30 young women with PCOS
and 30 healthy age- and body mass index (BMI)-matched
women. PCOS women had higher fasting glucose and insulin
levels, homeostasis model assessment score of insulin sensi-
tivity, total cholesterol (TC) and low density lipoprotein cho-
lesterol (LDL-C) levels, and TC/high density lipoprotein cho-
lesterol (HDL-C) ratio and lower HDL-C levels than controls.
Additionally, PCOS women had higher left atrium size (32.0
4.9 vs. 27.4  2.1 mm; P < 0.0001) and left ventricular mass
index (80.5 18.1 vs. 56.1 5.4 g/m2; P < 0.0001) and lower left
ventricular ejection fraction (64.4  4.1 vs. 67.1  2.6%; P 
0.003) and early to late mitral flow velocity ratio (1.6  0.4 vs.
2.1 0.2; P < 0.0001) than controls. When patients and controls
were grouped according to BMI [normal weight (BMI, >18 and
<25 kg/m2), overweight (BMI, 25.1–30 kg/m2), and obese (BMI,
>30 kg/m2)], the differences between PCOS women and con-
trols were maintained in overweight and obese women. In
normal weight PCOS women, a significant increase in left
ventricular mass index and a decrease in diastolic filling were
observed, notwithstanding no change in TC, LDL-C, HDL-C,
TC/HDL-C ratio, and TG compared with controls. In conclu-
sion, our data show the detrimental effect of PCOS on the
cardiovascular system even in young women asymptomatic
for cardiac disease. (J Clin Endocrinol Metab 89: 3696–3701,
2004)
THE POLYCYSTIC OVARY syndrome (PCOS) is one ofthe most common endocrine diseases in women, af-
fecting up to 10% of women in reproductive age (1, 2). PCOS
is characterized by chronic anovulatory cycles, oligo- or
amenorrhea, hirsutism, and insulin resistance; obesity is
also common (3–5). PCOS not only has a negative effect on
fertility, but it is also considered a clear-cut plurimetabolic
syndrome (2, 4, 6), being associated with type 2 diabetes
mellitus, hypertension, and dyslipidemia (7–9). Insulin
resistance is probably the major risk factor for the occur-
rence of cardiovascular (CV) disease (CVD) in PCOS (3).
The risk of coronary artery disease (10–12) and myocardial
infarction (13) has been reported to be increased in patients
with PCOS compared with regularly cycling women even if
mortality because of circulatory disease does not seem to be
increased (14–16). In PCOS women, endothelial and diastolic
dysfunction have been shown and associated with both el-
evated androgen levels and insulin resistance (17, 18). Re-
cently, together with classical CV risk factors, such as total
(TC) and high density lipoprotein cholesterol (HDL-C) lev-
els, obesity, homocysteine, and left ventricular (LV) hyper-
trophy (LVH) (19) have been shown to be independently
associated with an increased CV risk. LVH is an important
predictor of CV morbidity and mortality (20, 21), but deter-
minants of LV mass (LVM) in nonhypertensive subjects are
still incompletely understood (22–24).
The present study aims at further investigating the CV risk
of young women with PCOS. We 1) studied the prevalence
of LVH and altered diastolic filling and systolic performance
by echocardiography, and 2) analyzed any potential rela-
tionship between cardiac and metabolic parameters, such as
insulin secretion and lipid profile, in a selected cohort of 30
young women with PCOS.
Subjects and Methods
Subjects
Thirty young (35 yr) women with PCOS and 30 age- and body mass
index (BMI)-matched controls were enrolled in this pilot study. The
controls were defined as age- and BMI-matched with cases when the
number of years  age of cases and the BMI (kilograms per meter
squared) of cases were less than to 2 yr and less than to 1 kg/m2,
respectively.
PCOS was defined according to clinical [Ferriman-Gallwey score,8)
(25) oligomenorrhea or amenorrhea  6 months; biological LH/FSH
ratio,2; hyperandrogenism] and ultrasonographic (26, 27) findings. In
Table 1 are shown the clinical and biochemical diagnostic features of the
PCOS women.
The control group consisted of 30 healthy volunteer females with
Abbreviations: BMI, Body mass index; CV, cardiovascular; CVD, CV
disease; DBP, diastolic blood pressure; E/A, maximal early diastolic
flow velocity/maximal late diastolic flow velocity ratio; EDV, end-
diastolic volume; ESV, end-systolic volume; FAI, free androgen index;
HDL-C, high density lipoprotein cholesterol; HOMA, homeostasis
model assessment; LDL-C, low density lipoprotein cholesterol; LV, left
ventricular; LVEF, LV ejection fraction; LVH, LV hypertrophy; LVM, LV
mass; LVMi, LV mass index; PCOS, polycystic ovary syndrome; PRL,
prolactin; SBP, systolic blood pressure; TC, total cholesterol; TG,
triglycerides.
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regular menstrual cycles. Their healthy state was determined by medical
history, physical and pelvic examination, and complete blood chemistry.
The normal menstrual cycle was diagnosed after a 3-month prestudy
period. During this period, all healthy women recorded in a daily diary
the characteristics of their menses. A normal menstrual cycle was de-
fined as cyclic uterine bleedings with a duration of 4–5 d and a frequency
of 26–32 d/month. The quantity of blood flow was defined as normal
subjectively by each woman and objectively using a serum hemoglobin
assay. At the entry, the normal ovulatory state was confirmed by trans-
vaginal ultrasonography and plasma progesterone levels during the
luteal phase of the cycle.
Exclusion criteria for all subjects included age less than 18 or more
than 30 yr, pregnancy, hypothyroidism, hyperprolactinemia, Cushing’s
syndrome, nonclassical congenital adrenal hyperplasia, and current or
previous (within the last 6 months) use of oral contraceptives, glucocor-
ticoids, antiandrogens, ovulation induction agents, antidiabetic and an-
tiobesity drugs, or other hormonal drugs. The presence of hyperpro-
lactinemia was excluded with a single assay of plasma prolactin (PRL)
levels (normal, 25 ng/ml) (28). In women with a serum PRL levels
greater than 25 ng/ml, hyperprolactinemia was excluded considering
the average value of serum PRL assayed at 0800 h for three times every
15 min. Nonclassical congenital adrenal hyperplasia was excluded with
a single measure of serum 17-hydroxyprogesterone levels (normal,6.0
nmol/liter) (29).
Women with clinical and/or biochemical hyperandrogenism alone
were excluded from the control group. None of the patients was affected
by any neoplastic or cardiovascular disorder, and none of the women
(PCOS and controls) had hypertension or used any drug during the 3
months preceding the study. None of the women had a BMI less than
18 kg/m2.
The study was performed according to the guidelines of the Helsinki
Declaration on human experimentation and was approved by the local
ethics committee of University Federico II of Naples. All patients gave
their written informed consent before the study.
Study protocol
According to a previous study protocol (30) all patients and controls
were submitted to a three-step study.
Clinical study. Height, weight, BMI, waist to hip ratio, and measurements
of heart rate, systolic (SBP) and diastolic (DBP) blood pressure were
evaluated by standard methods. BMI was measured as the ratio between
the weight and the square of the height. A BMI between 25 and 30 kg/m2
was considered an index of overweight whereas a BMI greater than 30
kg/m2 was considered an index of obesity (31). The waist to hip ratio
was measured as the ratio between the waist, considered to be the
smallest circumference of torso between the 12th rib and the iliac crest,
and the circumference of the hip, considered as the maximal extension
of the buttocks. All measurements were performed when the patients
were in a standing position with relaxed abdomen, arms at their sides,
and joined feet (32). Blood pressure was measured in the right arm, with
the subjects in a relaxed sitting position. The average of six measure-
ments (three taken by each of two examiners) with a mercury sphyg-
momanometer was used.
Biochemical study. Fasting glucose, triglycerides (TG), TC, low density
lipoprotein cholesterol (LDL-C) and HDL-C levels were measured by
standard procedures in the morning between 0800 and 0900 h after an
overnight fast and resting in bed during early follicular phase (d 2–5) of
the spontaneous or progesterone-induced withdrawal bleeding. Sam-
ples were performed 10 min after needle insertion in duplicate and
immediately centrifuged, and the serum was stored at 80 C until
analysis. The TC/HDL-C ratio was also calculated for each woman (33).
Hypertriglyceridemia was diagnosed when triglycerides levels were
greater than 250 mg/dl (34), whereas hypercholesterolemia was diag-
nosed when total cholesterol levels were greater than 240 mg/dl (35).
Impaired glucose tolerance was diagnosed after an oral glucose toler-
ance test (75 g glucose diluted in 250 ml saline solution, measuring blood
glucose every 30 min for 2 h). In line with World Health Organization
criteria, diabetes mellitus was diagnosed when fasting blood glucose
levels were greater than 126 mg/dl in two consecutive determinations
or 200 mg/dl or more 2 h after oral glucose; reduced glucose tolerance
was diagnosed when blood glucose levels were 126–200 mg/dl 2 h after
oral glucose (36). Fasting and glucose load-stimulated insulin levels
were measured in patients and controls to estimate the insulin sensi-
tivity; the homeostasis model assessment (HOMA) index, which is con-
sidered an index of insulin resistance (37), was also calculated.
Echocardiographic study. M-Mode, two-dimensional, and pulsed Doppler
echocardiography studies were performed by one operator (L.S.), who
was blind with respect to the presence of metabolic abnormalities or
arterial hypertension, using ultrasound systems (Apogee CX, Interspec,
Inc., Ambler, PA) with a 3.5-mHz transducer during at least three con-
secutive cardiac cycles. All patients were studied in the left lateral
position after a 10-min resting period according to the recommendations
of the American Society of Echocardiography (38). The following mea-
surements were recorded on M-mode tracing: interventricular septum
and LV posterior wall thickness. The frequency-normalized mean ve-
locity of circumferential fiber shortening end-diastolic and end-systolic
volumes (EDV and ESV) and ejection fraction [EF  EDV  ESV/EDV
(%)] were estimated according to the Quinones method (39). The LV
ejection fraction (LVEF) is normal when it is above 50%. The LVM was
calculated by Devereux’s formula according to Penn’s convention with
the following regression-corrected cube formula: LVM  1.04[(ISV 
LVID  PWT)3  (LVID)3]  14 g. LVH was diagnosed when LVM
values, corrected for body surface area [LVM index (LVMi)], were 135
g/m2 or greater in males and 110 g/m2 or greater in females (40).
Doppler studies provided indexes of ventricular filling that were de-
rived from the mitral flow velocities curves, i.e. maximal early diastolic
flow velocity (E; centimeters per second), maximal late diastolic flow
velocity (A; centimeters per second), and the ratio between E and A
curves (E/A; normal, 1).
Assays
Plasma LH, FSH, PRL, estradiol, progesterone, testosterone, 4-
androstenedione, and dehydroepiandrosterone sulfate were measured
by specific RIA as previously described (41, 42). Serum 17-hydroxypro-
gesterone levels were determined by RIA (Diagnostic Systems Labora-
tories, Webster, TX) with a sensitivity of 0.01 ng/ml and intra- and
interassay coefficients of variation of 8.9% and 9.0%, respectively. SHBG
levels were measured using an immunoradiometric assay, as previously
described (28, 43). In each woman the free androgen index (FAI) was
calculated using the following formula: testosterone (nmol/liter)/
SHBG  100 (44).
Serum insulin was measured by a solid phase chemiluminescent
enzyme immunoassay using commercially available kits (Immunolite,
Diagnostic Products Corp., Los Angeles, CA). Blood glucose levels were
determined by the glucose oxidase method. Serum TC, HDL-C, LDL-C,
and TG levels were measured with an autoanalyzer (Monarch 1000,
Instrumentation Laboratory, Milan, Italy) using commercially available
kits (IL TEST, Instrumentation Laboratory) as previously reported (45,
46). Serum LDL-C was evaluated using Friedewald’s formula: TC 
HDL-C  1/5 TG (47).
TABLE 1. Clinical and biochemical diagnostic features of the 30
PCOS studied women
Features No. (%)
Anovulatory infertility 30 (100)
Normal FSH levels 30 (100)
Oligo/amenorrheaa 30 (100)
Clinical hyperandrogenisma 26 (86.7)
Hirsutismb 26 (86.7)
Acne 9 (30)
Biochemical hyperandrogenisma 15 (50)
T  2 nmol/liter 12 (40)
A  15 nmol/liter 11 (36.7)
DHEA-S  10 mol/liter 12 (40)
LH/FSH ratio 2 27 (90)
Polycystic ovary at TV-USG 24 (80)
T, Testosterone; A, androstenedione; DHEA-S, dehydroepiandro-
sterone sulfate; TV-USG, transvaginal ultrasonography.
a NIH PCOS criteria.
b As evaluated by Ferriman-Gallwey score.
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Statistical analysis
Statistical analysis was performed using the SPSS 11.5.2.1 package
(SPSS, Inc., Chicago, IL). Data were expressed as the mean  sd. Step-
wise multiple linear regression analysis was performed to evaluate the
relative importance of LVMi, as a dependent variable, against predictor
variables: age, BMI, HOMA, FAI, lipid profile, SBP, DBP, and number
of cigarettes smoked daily. Differences in physical activity and smoking
habitus (percentage of women smoking) were evaluated using Mann-
Whitney U test and 2 test, respectively. The other comparisons between
patients and controls were performed using a t test for unpaired data.
Significance was set at 5%.
Results
Clinical study (Table 2)
As expected, PCOS patients had significantly (P  0.05)
higher LH, testosterone, 4-androstenedione, and SHBG lev-
els than controls. DBP and mean blood pressure were also
significantly (P  0.05) higher in the patients than in the
controls, whereas SBP and heart rate were similar in the two
groups. The endocrine parameters were in line with the
diagnosis of PCOS in the patients group. In particular, the
FAI was significantly (P  0.05) higher in patients than
controls.
Biochemical study (Table 3)
PCOS patients had significantly (P  0.05) higher fasting
glucose and insulin levels, HOMA, TC, LDL-C, and TC/
HDL-C ratio, whereas HDL-C levels were significantly (P 
0.05) lower than control values. TG levels were similar in
patients and controls. Neither the patients nor the controls
had hypercholesterolemia or hypertriglyceridemia.
Echocardiography study (Table 4)
Young women with PCOS had a cardiac size significantly
(P  0.05) increased compared with controls. They had also
interventricular septum, LV posterior wall thickness, ESV,
and LVMi significantly (P  0.05) higher than controls. Two
of 30 (6.7%) had LVH (110 g/m2). Additionally, PCOS
patients had significantly (P  0.05) lower LVEF and E/A
than controls, although all patients had normal LVEF, and
two patients had abnormal E/A (6.7%).
When patients and controls were grouped according to
BMI into three groups, namely subjects of normal weight
(BMI, 18  25 kg/m2), overweight (BMI, 25.1–30 kg/m2),
and obese (BMI, 30 kg/m2), it was observed that the ma-
jority of the differences in the metabolic profile and cardiac
findings persisted (Table 5). As expected, there was a pro-
gressive impairment of metabolic profile and echocardio-
graphic pattern from patients with normal weight to those
with obesity (Table 5). Interestingly, normal weight PCOS
women had a significant (P  0.05) increase in LVMi and a
decrease in diastolic filling, but no difference in TC, LDL-C,
HDL-C, TC/HDL-C ratio, or TG, compared with controls.
The other two groups had the same pattern described in the
series of patients as a whole.
The final model of stepwise multiple linear regression
analysis in PCOS patients showed that LVMi is linearly re-
lated only to HOMA (coefficient  6.764;  0.874; P 
0.0001; constant  58.647).
Discussion
The results of this prospective controlled study in selected
young women with PCOS showed a significant impairment
TABLE 3. Metabolic profile and cardiovascular risk factors in
women with and without PCOS
PCOS Controls P
Fasting glucose (mmol/liter) 5.3  2.6 2.6  0.6 0.0001
Fasting insulin (pmol/liter) 12.9  5.2 2.3  0.9 0.0001
HOMA 3.2  2.0 0.3  0.1 0.0001
TC (mmol/liter) 4.2  0.5 3.5  0.4 0.0001
LDL-C (mmol/liter) 2.3  0.4 1.8  0.3 0.0001
HDL-C (mmol/liter) 2.5  0.5 2.9  0.3 0.0001
TC/HDL-C ratio 1.7  0.4 1.2  0.4 0.0001
TG (mmol/liter) 1.5  0.2 1.4  0.2 0.06
TABLE 4. Echocardiographic findings in PCOS and controls
PCOS Controls P
LV diastolic diameter (mm) 46.0  3.9 42.9  1.7 0.1
LV systolic diameter (mm) 26.6  4.3 23.0  1.8 0.001
IST (mm) 8.3  1.2 6.7  0.8 0.0001
LV posterior wall thickness
(mm)
8.1  1.5 6.6  0.8 0.0001
LVMi (g/m2) 80.5  14.8 56.1  5.4 0.0001
Left atrium size (mm) 32.0  4.9 27.4  2.1 0.0001
Aorta size (mm) 28.9  3.5 28.0  1.3 0.1
LVEF (%) 64.4  4.1 67.1  2.6 0.003
Early to late mitral flow
velocity
1.6  0.4 2.1  0.2 0.0001
IST, Interventricular septum thickness.
TABLE 2. Demographic and endocrine profile in 30 young
patients with clinical, ultrasonographic, and endocrine diagnosis of
PCOS and 30 age- and BMI-matched controls
PCOS Controls Pa
Age (yr) 24.3  5.6 24.8  4.2 0.70
BMI (kg/m2) 28.7  6.7 27.3  5.0 0.36
WHR 0.94  0.23 0.87  0.06 0.11
Physical activity scoreb 2.1  0.4 2.0  0.3 0.27
Smoking habitus
No. of smokers (%)c 10 (33.3) 8 (26.7) 0.57
No. of cigarettes daily 4.2  1.3 5.6  1.4 0.15
HR (beats/min) 78.3  5.9 76.2  4.4 0.12
SBP (mm Hg) 112  3.0 110  3.8 0.6
DBP (mm Hg) 72  8.1 67.0  6.0 0.005
DP (mm Hg) 40.1  10.2 44.7  10.8 0.26
MBP (mm Hg) 84.9  8.3 80.5  5.7 0.04
Serum hormone levels
FSH (IU/liter) 7.8  4.5 9.1  0.6 0.15
LH (IU/liter) 23.5  4.5 9.1  1.5 0.0001
PRL (g/liter) 14.0  9.2 12.3  1.1 0.24
E2 (pmol/liter) 55.8  24.3 52.2  2.2 0.32
17-OH-P (nmol/liter) 2.8  3.5 0.7  0.2 0.005
T (nmol/liter) 2.4  1.3 0.5  0.2 0.0001
A4 (nmol/liter) 4.1  1.9 1.0  0.3 0.0001
DHEA-S (mol/liter) 4.4  1.3 4.0  1.0 0.17
SHBG (nmol/liter) 28.6  5.7 50.4  3.5 0.0001
FAI (%) 8.6  5.0 1.0  0.5 0.0001
WHR, Waist/hip ratio; HR, heart rate; DP, differential pressure;
MBP, mean blood pressure; E2, estradiol; 17-OH-P, 17-hydroxypro-
gesterone; T, testosterone; A, androstenedione; DHEA-S, dehydro-
epiandrosterone sulfate.
a By unpaired t test except when indicated.
b By Mann-Whitney U test.
c By 2 test.
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of glucose and lipid profile associated with an increased
LVM and decreased LV performance and diastolic filling.
Most of these abnormalities persisted even in young patients
with normal weight, suggesting that the pathogenesis of
cardiac abnormalities in PCOS is not only dependent on BMI.
In fact, only in the patients was LVMi significantly correlated
with both BMI and HOMA index.
PCOS women represent an intriguing biological model
illustrating hormonal effects on cardiovascular risk. In fact,
several findings indicate a relationship between heart disease
and PCOS, i.e. dyslipidemia (9), insulin resistance (3, 7),
increased LVM, and diastolic dysfunction (48, 49). PCOS as
a putative cause of CVD is, however, still questioned, be-
cause definitive data to demonstrate a direct influence of
PCOS on heart disease are still lacking (50–52). On the basis
of the multiple findings linking CVD with PCOS, we de-
signed this prospective controlled study to investigate dif-
ferent variables affecting heart structure and function. We
selected a group of young patients to exclude any role of
long-standing undiagnosed PCOS and investigated the early
phases of the disease. To better understand the role of in-
creased BMI frequent in PCOS, we included a group of lean
patients and controls. This would allow us to detect cardiac
abnormalities not related to overweight and obesity.
PCOS women were reported to have higher TG levels and
lower HDL-C values (53). Because insulin is a major positive
regulator of lipoprotein lipase that is involved in the path-
way of HDL-C production, dyslipidemia is probably sec-
ondary to insulin resistance, although hyperandrogenism
may affect lipoproteins and lipids independently of insulin
levels and body weight (9). In our series we confirmed an
unfavorable lipid profile; however, we did not find any in-
crease in TG levels. Our young patients with PCOS had an
increase in TC and a decrease in HDL-C levels as major
findings associated with increased glucose and insulin levels
and HOMA index. We also confirmed increased LVM and
diastolic dysfunction in young PCOS women. Interestingly,
these abnormal echocardiographic aspects were present even
in the 12 normal weight women who did not show alterations
in lipid profile. Furthermore, these young PCOS women
showed greater LVMi than their age- and BMI-matched con-
trols. Although it is well known that ventricular mass in-
dexed for height is significantly higher in overweight than in
normal weight subjects (54), our PCOS women showed an
increased LVMi that was not weight dependent. Therefore,
PCOS could be considered an aggravating factor causing
LVH and could play a role in the early cardiovascular disease
in PCOS. Among the various echocardiographic parameters
that were different between PCOS and controls, the increased
LVMi in young PCOS patients has clinical importance, be-
cause it represents the main cause of both LVH and diastolic
dysfunction in PCOS women, worsening from early to el-
derly age.
LVH is one of the several metabolic and cardiovascular
risk factors associated with insulin resistance (55) and/or
visceral obesity (56). In our series, there was a linear relation
between LVMi and HOMA. Hyperinsulinemia is a predictor
of coronary artery disease (57–60), and insulin resistance has
been proposed as the key factor linking hypertension, glu-
cose intolerance, obesity, lipid abnormalities, and coronary
heart disease in an association called metabolic syndrome X
(61). In fact, the increased LVM in PCOS women could be
caused by an increase in blood pressure, even in the absence
of hypertension (62). Indeed, in our series we found slightly
increased mean blood pressure and DBP in PCOS women
compared with controls.
In accord with previous studies (48, 49), we also report
diastolic dysfunction in PCOS. Specifically, Tiras et al. (49)
suggested that patients with PCOS have diastolic dysfunc-
tion; furthermore, no difference in E/A was observed be-
tween PCOS and control women. On the contrary, we
showed both reduced ejection fraction of LV and E/A, sug-
gesting impaired LV diastolic filling. However, whether the
E/A ratio is an early predictor of diastolic dysfunction in
PCOS remains to be determined. In addition, Prelevic et al.
(63) reported that systolic flow velocity is lower in PCOS than
in age-matched control women, and there is an inverse re-
lationship between serum fasting insulin and LV systolic
outflow parameters; furthermore, increased insulin levels in
PCOS are associated with decreased cardiac flow (63).
Although we did not find any association between LVM
or diastolic dysfunction and hyperandrogenism, cross-
sectional data consistently showed a strong obesity-inde-
pendent association of androgen excess in women with a
cluster of CVD risk factors, including insulin resistance, dys-
lipidemia, and impaired fibrinolysis. It was therefore sug-
TABLE 5. Main cardiovascular risk factors and echocardiographic findings in patients and controls according to BMI
BMI 18–25 kg/m2 BMI 25.1–30 kg/m2 BMI 30 kg/m2
PCOS Controls P PCOS Controls P PCOS Controls P
No. 12 12 6 6 12 12
FAI (%) 9.1  6.2 1.0  0.5 0.0001 10.8  2.5 0.8  0.5 0.0001 7.1  5.0 1.1  0.4 0.0001
Fasting insulin (pmol/liter) 9.0  4.3a 2.2  0.8 0.0001 10.3  3.0a 2.7  1.0 0.0001 18  7.3 2.3  1.0 0.0001
HOMA 1.8  0.8b 0.3  0.1 0.0001 2.5  1.2a 0.3  0.1 0.001 4.9  3.7 0.3  0.1 0.0001
TC (mmol/liter) 3.6  0.4 3.4  0.3 0.180 4.6  0.6 3.5  0.5 0.006 4.8  0.5 3.7  0.4 0.0001
LDL-C (mmol/liter) 2.0  0.4 1.7  0.3 0.142 2.3  0.3 1.8  0.2 0.007 2.5  0.5 1.9  0.4 0.004
HDL-C (mmol/liter) 2.4  0.6 2.7  0.3 0.136 2.5  0.3 2.9  0.2 0.022 2.6  0.3 3.0  0.4 0.011
TC/HDL-C ratio 1.5  0.4 1.2  0.3 0.050 1.8  0.5 1.2  0.4 0.045 1.8  0.3 1.2  0.5 0.002
TG (mmol/liter) 1.3  0.2 1.2  0.3 0.347 1.5  0.3 1.4  0.2 0.512 1.6  0.2 1.5  0.2 0.234
LVMi (g/m2) 70.2  19.1a 56.2  4.3 0.021 77.7  8.2 56.3  8.7 0.001 92.2  14 55.8  4.9 0.0001
LVEF (%) 65.9  3.4 67.7  3.0 0.183 65.5  4.8 66.2  2.6 0.760 62.2  3.7 66.7  1.9 0.001
Early to late mitral flow velocity 1.7  0.3 2.0  0.1 0.003 1.4  0.3 1.9  0.1 0.003 1.5  0.4 2.1  0.1 0.0001
a P  0.05 vs. PCOS patients with BMI greater than 30 kg/m2.
b P  0.05 vs. PCOS patients with BMI of 25.1–30 and greater than 30 kg/m2.
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gested that the chronically abnormal hormonal and meta-
bolic milieu found in women with PCOS, starting from
adolescence, may predispose these women to premature ath-
erosclerosis. Furthermore, based on calculated risk profiles,
PCOS women were predicted to have a 7-fold increased
relative risk for myocardial infarction; in fact, Birdsall et al.
(11) showed significant associations between the presence of
polycystic ovaries and the presence and severity of cardio-
vascular artery disease and a family history of myocardial
infarction as well as with elevated levels of insulin and TG
and lower levels of HDL-C (11).
Some findings of clinical studies showed that women with
CVD were affected more frequently than controls by clinical
symptoms of androgen excess, such as hirsutism and poly-
cystic ovaries (3, 4, 50, 64). Because many women with PCOS
are overweight, and most, if not all, are insulin resistant, it
is a matter of debate whether these symptoms are secondary
to obesity and insulin resistance or whether hyperandro-
genism itself contributes to obesity, insulin resistance, and
hyperinsulinemia.
Our findings suggest that young PCOS women have in-
creased LVM and diastolic dysfunction, neither of which is
weight dependent, demonstrating that PCOS women are
candidates for early CVD. Additional studies are needed to
better clarify the exact role of insulin resistance and/or hy-
perandrogenism in the CVD, particularly in the complex
etiopathogenetic scenario of the increased LVM in young
PCOS patients.
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